MarketCap
Facebook
X
TelegramQuarterly report 2024-Q2
added 08-07-2024
Alimera Sciences Net Income 2011-2025 | ALIM
Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.
Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]
It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.
The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.
Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.
It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.
However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.
Annual Net Income Alimera Sciences
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -20.1 M | -18.1 M | -4.37 M | -5.34 M | -10.4 M | -16.4 M | -22 M | -33.2 M | -30.6 M | -35.9 M | -46.2 M | -19.7 M | -22.5 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -4.37 M | -46.2 M | -21.9 M |
Quarterly Net Income Alimera Sciences
| 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -3.31 M | -6.25 M | - | -10 M | -4.97 M | - | -5.26 M | -3.12 M | -5.96 M | - | -4.18 M | 7.56 M | -3.65 M | - | -618 K | -2.55 M | -1.2 M | - | -3.14 M | -5.04 M | -2.76 M | - | -3.45 M | -4 M | -7.68 M | -7.22 M | -5.28 M | -2.76 M | -6.74 M | -5.93 M | -9.24 M | -6.86 M | -11.1 M | -10.7 M | -1.54 M | -8.6 M | -9.79 M | -10 M | -7.01 M | 1.12 M | -20.8 M | - | -1.11 M | -16.4 M | -14 M | - | -5.39 M | -4.7 M | -4.36 M | - | -6.54 M | -5.21 M | -4.7 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 7.56 M | -20.8 M | -5.78 M |
References
- Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.
Net Income of other stocks in the Drug manufacturers industry
| Issuer | Net Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Aerie Pharmaceuticals
AERI
|
-74.8 M | - | - | $ 754 M |  USA |
 |
Canopy Growth Corporation
CGC
|
-598 M | $ 1.24 | -5.73 % | $ 133 M |  Canada |
 |
AcelRx Pharmaceuticals
ACRX
|
-13 M | - | 7.5 % | $ 6.35 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
-26.5 M | - | 0.86 % | $ 117 M | USA |
 |
Cronos Group
CRON
|
-73.1 M | $ 2.69 | -2.01 % | $ 1.44 B | Canada |
 |
Agile Therapeutics
AGRX
|
-14.5 M | - | 10.11 % | $ 58.2 M | USA |
 |
Catalent
CTLT
|
-1.04 B | - | - | $ 11.5 B | USA |
 |
Aurora Cannabis
ACB
|
-695 M | $ 4.52 | -1.09 % | $ 86.3 M | Canada |
 |
DURECT Corporation
DRRX
|
-27.6 M | - | - | $ 50.1 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
35.6 M | - | -39.89 % | $ 27.7 M | USA |
 |
Endo International plc
ENDP
|
-2.45 B | - | - | $ 28.9 M |  Irlanda |
 |
Evoke Pharma
EVOK
|
-7.79 M | - | - | $ 36.6 M | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
-510 M | - | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
-115 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Emergent BioSolutions
EBS
|
-760 M | $ 12.28 | -3.0 % | $ 629 M | USA |
 |
Athenex
ATNX
|
-103 M | - | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
-48.8 M | $ 21.59 | 0.02 % | $ 2.05 B |  France |
 |
Evolus
EOLS
|
-50.4 M | $ 6.79 | -0.95 % | $ 421 M | USA |
 |
Harrow Health
HROW
|
-24.4 M | $ 50.31 | 0.3 % | $ 1.64 B | USA |
 |
China Pharma Holdings
CPHI
|
-4.74 M | $ 1.18 | -9.92 % | $ 20.6 M |  China |
 |
OrganiGram Holdings
OGI
|
-131 M | $ 1.78 | 0.85 % | $ 402 M | Canada |
 |
Organogenesis Holdings
ORGO
|
861 K | $ 5.37 | -8.6 % | $ 707 M | USA |
 |
Bausch Health Companies
BHC
|
-592 M | $ 7.17 | -0.35 % | $ 2.62 B | Canada |
 |
Pacira BioSciences
PCRX
|
-99.6 M | $ 26.42 | 1.54 % | $ 1.22 B | USA |
 |
Lannett Company
LCI
|
-232 M | - | 1.15 % | $ 7.11 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
13.7 M | - | - | $ 193 M | Canada |
 |
Cumberland Pharmaceuticals
CPIX
|
-1.9 M | $ 4.16 | -0.95 % | $ 58.5 M | USA |
 |
Rockwell Medical
RMTI
|
-8.44 M | $ 0.82 | 0.95 % | $ 19.1 M | USA |
 |
Solid Biosciences
SLDB
|
-125 M | $ 5.9 | - | $ 241 M | USA |
 |
Sundial Growers
SNDL
|
-230 M | $ 1.73 | -2.26 % | $ 3.37 M | Canada |
 |
Sonoma Pharmaceuticals
SNOA
|
-3.46 M | $ 3.53 | -3.16 % | $ 4.38 M | USA |
 |
PetIQ
PETQ
|
2.13 M | - | 1.64 % | $ 400 M | USA |
 |
Radius Health
RDUS
|
-70.2 M | - | - | $ 1.42 B | USA |
 |
Recro Pharma
REPH
|
-13.3 M | - | -4.76 % | $ 65.3 M | USA |
 |
Jupiter Wellness
JUPW
|
-49.4 M | - | - | $ 33.6 M | USA |
 |
Perrigo Company plc
PRGO
|
-172 M | $ 13.78 | 0.29 % | $ 1.89 B | USA |
 |
ProPhase Labs
PRPH
|
18.5 M | $ 0.52 | -15.2 % | $ 8.24 M | USA |
 |
Relmada Therapeutics
RLMD
|
-98.8 M | $ 4.47 | -2.88 % | $ 135 M | USA |
 |
Veru
VERU
|
-37.8 M | $ 2.3 | -1.71 % | $ 310 M | USA |
 |
cbdMD
YCBD
|
-153 K | $ 1.67 | 2.45 % | $ 7.2 M | USA |
 |
OptiNose
OPTN
|
-35.5 M | - | - | $ 1.08 B | USA |
 |
Assertio Holdings
ASRT
|
-332 M | $ 9.68 | -2.21 % | $ 688 M | USA |
 |
PLx Pharma
PLXP
|
-46.1 M | - | -27.8 % | $ 2.56 M | USA |
 |
SCYNEXIS
SCYX
|
67 M | $ 0.58 | -2.39 % | $ 27.8 M | USA |
 |
Tricida
TCDA
|
-177 M | - | - | $ 3.25 M | USA |
 |
Tilray
TLRY
|
-1.45 B | $ 9.71 | -4.34 % | $ 6 B | Canada |
 |
TherapeuticsMD
TXMD
|
-10.3 M | $ 1.7 | - | $ 17.7 M | USA |
 |
Viatris
VTRS
|
2.08 B | $ 12.33 | 0.71 % | $ 14.9 B | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
-35 M | - | - | $ 55.5 M | USA |